Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Global Genome Editing Market By Technique (CRISPR, Zinc Finger Nucleases, TALENs, Restriction enzymes, Others), By Applications (Synthetic Biology,…
LONDON–(BUSINESS WIRE)–#CompetitiveIntelligence–Infiniti Research is a leading provider of market intelligence services to businesses around the globe. For over 15 years,…
WALTHAM, Mass.–(BUSINESS WIRE)–Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and…
Rebound hypoglycemia observed in the placebo arm with oral glucose tablet use; No rebound hypoglycemia observed in the RTU glucagon…
First-in-human phase 1 trial initiated with DS-6157, a GPR20 directed ADC, in patients with advanced gastrointestinal stromal tumor (GIST) GIST…
Applications based on positive results from pivotal KarMMa study in relapsed and refractory multiple myeloma and QUAZAR®-AML-001 study in acute…
DUBLIN–(BUSINESS WIRE)–The “Aztreonam Injection Market Insights 2020 – Analysis and Forecasts for the Global and Chinese Markets to 2025, by…
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
Designation follows recent U.S. Breakthrough Therapy Designations for ENHERTU for HER2 positive metastatic gastric cancer and HER2 mutant metastatic non-small…
Teva will present new data on Ajovy and on the long-term safety and efficacy of Copaxone at at the 6th Congress of the European Academy of Neurology